SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

FRAX1036

Item No. 20711

CAS Registry No.:	1432908-05-8
Formal Name:	6-[2-chloro-4-(6-methyl-2-pyrazinyl) phenyl]-8-ethyl-2-[[2-(1-methyl-4-piperidinyl)ethyl]amino]-pyrido[2,3-d] pyrimidin-7(8H)-one
MF:	$C_{28}H_{32}ClN_7O$
FW:	518.1
Purity:	≥98%
UV/Vis.:	λ_{max}: 211, 299, 308, 355 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

FRAX1036 is supplied as a crystalline solid. A stock solution may be made by dissolving the FRAX1036 in the solvent of choice. FRAX1036 is soluble in organic solvents such as ethanol and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of FRAX1036 in these solvents is approximately 0.33 and 1 mg/ml, respectively.

FRAX1036 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, FRAX1036 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. FRAX1036 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

FRAX1036 is a selective inhibitor of p21-activated kinase 1 (PAK1), a serine/threonine kinase downstream of Rac1 and Cdc42 that is involved in tumorigenesis. It can induce apoptosis in breast cancer cells and has been shown to potentiate the activity of the microtubule stabilizing agent, docetaxel (Item No. 11637).[1] Disruption of PAK1 *via* FRAX1036 has been used to inhibit oncogenic KRAS signaling in non-small cell lung cancer cells.[2]

References

1. Ong, C.C., Gierke, S., Pitt, C., *et al.* Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. *Breast Cancer Res.* **17(59)** (2015).
2. Mortazavi, F., Lu, J., Phan, R., *et al.* Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. *BMC Cancer* **15(381)** (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM